权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Increasing access to medication-assisted treatment: Interactions between federal and state workforce policies

增加获得药物辅助治疗的机会：联邦和州劳动力政策之间的相互作用

基本信息

批准号：
9887141
负责人：
JOANNE E. SPETZ
金额：
$ 36.28万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2023-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9887141
关键词：
Address Advanced Practice Nurse Affect Area Buprenorphine Certified registered nurse anesthetist Clinical Nurse Specialists Clinical Trials Collaborations Communities County Cross-Sectional Studies Data Data Sources Effectiveness Environmental Policy Geographic Distribution Geography Goals Grant Growth Health Personnel Health Services Accessibility Healthcare Individual Laws Light Link Measures Medical Methadone Morbidity - disease rate Naltrexone Nurse Midwives Nurse Practitioners Observational Study Opiate Addiction Opioid Patients Pharmaceutical Preparations Pharmacotherapy Physician Assistants Physicians Policies Population Heterogeneity Provider Records Recovery Regulation Relapse Reporting Research Site Statutes and Laws Supervision System Tennessee Variant West Virginia addiction authority base buprenorphine treatment cost design econometrics economic cost federal policy medication-assisted treatment mortality multiple data sources opioid abuse opioid epidemic opioid mortality opioid overdose opioid use disorder overdose death population health programs response rural area rural underserved social stem success waiver

项目摘要

ABSTRACT / PROJECT SUMMARY Medication treatment for opioid use disorder is an important component of efforts to reduce the high social costs of prescription and non-prescription opioid abuse and mortality. This approach incorporates pharmacotherapies (e.g., buprenorphine, methadone, naltrexone) as part of treatment for opioid dependence. Buprenorphine’s effectiveness has been established in numerous studies and can be prescribed in office-based settings; thus, buprenorphine is particularly important to the expansion of access to medication treatment for opioid use disorder. However, the need for treatment dramatically outstrips the number of providers authorized to prescribe it, with particularly severe shortages of providers in rural areas. Many U.S. counties do not have a single provider. In response to the shortage of buprenorphine prescribers, two federal workforce policies were established in 2016: (1) allowing nurse practitioners and physician assistants to become authorized to prescribe buprenorphine in office-based settings, and (2) increasing the maximum number of patients that can be prescribed buprenorphine by a physician from 100 to 275. Legislation passed in 2018 allows other advanced practice nurses (nurse-midwives, clinical nurse specialists, and nurse-anesthetists) to prescribe buprenorphine as well. These policies are expected to increase access to medication treatment for opioid use disorder for thousands of individuals. However, the degree to which these policies achieve their goal will depend on other environmental and policy factors, most importantly state laws that regulate advanced practice clinicians’ medication prescribing. The proposed study will assess the impacts of these workforce policies on the supply and geographic reach of opioid treatment providers, with a focus on whether and how state policies facilitate or impede growth in available prescribers. The specific aims are: Aim 1: To measure the degree to which federal policies established in 2016 and 2018 impact the number and geographic distribution of clinicians with buprenorphine waivers. Aim 2: To determine whether state-level scope of practice regulations persistently moderate the effectiveness of federal policies aimed at increasing access to buprenorphine treatment. Aim 3: To assess whether expansions of the number and types of clinicians authorized to prescribe buprenorphine are associated with greater dispensing of buprenorphine. Data from multiple sources from 2016 through 2022 will be analyzed using econometric approaches that address state variation in regulations that may affect the growth of buprenorphine prescribers and utilization while controlling for other regulations and programs that might affect policy implementation. Findings from this research could be used to promote the harmonization of state and federal efforts to address the opioid crisis across the U.S. and in highly-impacted regions.

摘要/项目总结